Yan S, Ren J, Su H, Ma J, He W, Cai X
Heliyon. 2024; 10(14):e32945.
PMID: 39100487
PMC: 11295978.
DOI: 10.1016/j.heliyon.2024.e32945.
Kelly M, Dietz C, Kasson S, Zhang Y, Holtzman M, Kim I
Biochem Biophys Res Commun. 2024; 720:150101.
PMID: 38749191
PMC: 11219154.
DOI: 10.1016/j.bbrc.2024.150101.
Dhakar S, Galera-Prat A, Lehtio L
Sci Rep. 2024; 14(1):3875.
PMID: 38365924
PMC: 10873324.
DOI: 10.1038/s41598-024-54123-8.
Bourlon M, Valdez P, Castro E
Ther Adv Med Oncol. 2024; 16:17588359231221337.
PMID: 38205078
PMC: 10777773.
DOI: 10.1177/17588359231221337.
Macchia G, Titone F, Restaino S, Arcieri M, Pellecchia G, Andreetta C
Healthcare (Basel). 2023; 11(17).
PMID: 37685447
PMC: 10486999.
DOI: 10.3390/healthcare11172413.
Synthesis and Degradation of Poly(ADP-ribose) in Zebrafish Brain Exposed to Aluminum.
Bianchi A, La Pietra A, Guerretti V, De Maio A, Capriello T, Ferrandino I
Int J Mol Sci. 2023; 24(10).
PMID: 37240112
PMC: 10218123.
DOI: 10.3390/ijms24108766.
The function and regulation of ADP-ribosylation in the DNA damage response.
Duma L, Ahel I
Biochem Soc Trans. 2023; 51(3):995-1008.
PMID: 37171085
PMC: 10317172.
DOI: 10.1042/BST20220749.
Zinc finger transcription factor CASZ1b is involved in the DNA damage response in live cells.
Liu Z, Kruhlak M, Thiele C
Biochem Biophys Res Commun. 2023; 663:171-178.
PMID: 37121127
PMC: 10880029.
DOI: 10.1016/j.bbrc.2023.04.085.
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J, Gawalski K, Szredzka A, Suskiewicz M, Nowis D
Front Mol Biosci. 2022; 9:1073797.
PMID: 36533080
PMC: 9751342.
DOI: 10.3389/fmolb.2022.1073797.
Quantitative Analysis of Nuclear Poly(ADP-Ribose) Dynamics in Response to Laser-Induced DNA Damage.
Koczor C, Saville K, Al-Rahahleh R, Andrews J, Li J, Sobol R
Methods Mol Biol. 2022; 2609:43-59.
PMID: 36515828
PMC: 9920208.
DOI: 10.1007/978-1-0716-2891-1_3.
Recent Advances for Drought Stress Tolerance in Maize ( L.): Present Status and Future Prospects.
Sheoran S, Kaur Y, Kumar S, Shukla S, Rakshit S, Kumar R
Front Plant Sci. 2022; 13:872566.
PMID: 35707615
PMC: 9189405.
DOI: 10.3389/fpls.2022.872566.
Pleiotropic role of PARP1: an overview.
Kumar V, Kumar A, Mir K, Yadav V, Chauhan S
3 Biotech. 2021; 12(1):3.
PMID: 34926116
PMC: 8643375.
DOI: 10.1007/s13205-021-03038-6.
Therapeutic Significance of microRNA-Mediated Regulation of PARP-1 in SARS-CoV-2 Infection.
Dash S, Dash C, Pandhare J
Noncoding RNA. 2021; 7(4).
PMID: 34698261
PMC: 8544662.
DOI: 10.3390/ncrna7040060.
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L, McClay E, Patel S, Schimpl M, Spagnolo L, De Oliveira T
Int J Mol Sci. 2021; 22(10).
PMID: 34066057
PMC: 8150716.
DOI: 10.3390/ijms22105112.
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
Verma P, Zhou Y, Cao Z, Deraska P, Deb M, Arai E
Nat Cell Biol. 2021; 23(2):160-171.
PMID: 33462394
PMC: 7880902.
DOI: 10.1038/s41556-020-00624-3.
Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective.
Wang R, Cong Y, Li M, Bao J, Qi Y, Zhang J
Front Mol Biosci. 2020; 7:50.
PMID: 32373627
PMC: 7179655.
DOI: 10.3389/fmolb.2020.00050.
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy.
Jannetti S, Zeglis B, Zalutsky M, Reiner T
Front Pharmacol. 2020; 11:170.
PMID: 32194409
PMC: 7062869.
DOI: 10.3389/fphar.2020.00170.
Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy.
Song Z, Wang Y, Xiao Q, Yu Z, Zhao L, Wu H
Oncol Lett. 2018; 16(5):5621-5630.
PMID: 30344717
PMC: 6176245.
DOI: 10.3892/ol.2018.9398.
Structure of human ADP-ribosyl-acceptor hydrolase 3 bound to ADP-ribose reveals a conformational switch that enables specific substrate recognition.
Pourfarjam Y, Ventura J, Kurinov I, Cho A, Moss J, Kim I
J Biol Chem. 2018; 293(32):12350-12359.
PMID: 29907568
PMC: 6093245.
DOI: 10.1074/jbc.RA118.003586.
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Bitler B, Watson Z, Wheeler L, Behbakht K
Gynecol Oncol. 2017; 147(3):695-704.
PMID: 29037806
PMC: 5698126.
DOI: 10.1016/j.ygyno.2017.10.003.